Size | Price | Stock | Qty |
---|---|---|---|
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
Purity: ≥98%
Cefaclor (trade name: Ceclor; Biocef, Medacef, Distaclor, Keflor, Raniclor among others) is a potent, second-generation cephalosporin / beta-lactam antibiotic approved for use in the treatment of certain bacterial infections such as pneumonia and infections of the ear, skin, throat, lung, and urinary tract. It acts by binding specifically to penicillin-binding protein 3 (PBP 3)and inhibiting cell wall synthesis. Cefaclor is active against a wide spectrum of common pathogens, including gram-positive and gram-negative bacteria. Cefaclor binds to and inactivates penicillin-binding proteins (PBP) located in bacterial cytoplasmic membranes. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity.
Molecular Formula |
C15H14CLN3O4S
|
---|---|
Molecular Weight |
367.81
|
Exact Mass |
367.04
|
Elemental Analysis |
C, 48.98; H, 3.84; Cl, 9.64; N, 11.42; O, 17.40; S, 8.72
|
CAS # |
53994-73-3
|
Related CAS # |
Cefaclor monohydrate;70356-03-5;Cefaclor-d5;1426173-90-1
|
Appearance |
Solid powder
|
SMILES |
C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl
|
InChi Key |
QYIYFLOTGYLRGG-GPCCPHFNSA-N
|
InChi Code |
InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
|
Chemical Name |
(6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
Synonyms |
S6472; Cefaclor Anhydrous; Ceclor; Lilly 99638; Monohydrate, Cefaclor;Cefaclorum; Cephaclor; Raniclor; Kefral; Cefaclor Monohydrate; Keclor; S 6472; S-6472;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~18.5 mg/mL (~50.30 mM)
H2O : ~3.85 mg/mL (~10.47 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 3.33 mg/mL (9.05 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7188 mL | 13.5940 mL | 27.1880 mL | |
5 mM | 0.5438 mL | 2.7188 mL | 5.4376 mL | |
10 mM | 0.2719 mL | 1.3594 mL | 2.7188 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00257140 | COMPLETED | Drug: levofloxacin | Bronchitis Bronchitis, Chronic |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
1931-06 | Phase 2 Phase 3 |
NCT01449136 | COMPLETED | Other: Antibacterial cement | Dental Caries | University of Pernambuco | 2008-01 | Not Applicable |
NCT04713436 | COMPLETED | Drug: Differentiation Markers | Anti-Bacterial Agents Stem Cells |
Eskisehir Osmangazi University | 2014-01-01 | |
NCT01561703 | COMPLETEDWITH RESULTS | Drug: Antibiotic | Snoring Strep Throat |
University of Missouri-Columbia | 2012-03 | Not Applicable |
NCT02490293 | COMPLETEDWITH RESULTS | Drug: Cephalosporin Drug: Placebo |
Acute Cholecystitis | Taeho Hong | 2015-06 | Not Applicable |